Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Events According to Revascularization Modality in the ISCHEMIA Trial

The main studies carried out on patients with chronic coronary syndromes (CCS), such as the MASS II, COURAGE, BARI 2D and FAME-2, failed to show benefits in terms of mortality with the invasive approach. 

Eventos según modo de revascularización en el Ischemia Trial

The ISCHEMIA, a large randomized study including patients with moderate to severe ischemia, with without left main disease and with acceptable or no angina, also failed to show benefits as to reducing the risk of ischemic events when opting for an invasive strategy (INV) vs. a conservative strategy (CON) with medical treatment at mean 3.2 years.

Of the 2054 INV patients, 74.1% received PCI, while 25.8% opted for CABG. An ad-hoc analysis of the ISCHEMIA compared events related to INV-PCI and INV CABG, taking into account revascularization modality was not random. The aim of this study was to assess the risk of early and late events associated to each strategy. Primary end point was a composite of cardiovascular death, myocardial infarction (MI), hospitalization for unstable angina, cardiac failure or resuscitated cardiac arrest. 

The analysis looked at INV-MED (from randomization to revascularization), INV-PCI and INV-CABG strategy outcomes, and compared them to the CON strategy outcomes. They analyzed events at 30 days (early) and beyond 30 days (late).

Read also: Coronary Artery Disease in TAVR: Unsolved Dilemma.

Mean time from randomization to revascularization was 22 days for PCI and 44 days for CABG. Of the 512 INV-CABG patients, 16.4% experienced primary end outcomes at mean 2.85 years, with 57.1% of these events occurring within 30 days (83.3% were MI). Of the 1500 INV-PCI, 9.8% presented primary end outcomes at mean 2.94 years, with 21.1% early occurrence (77.4% of these early events were MI). When comparing against the 2591 CON patients, 13.6% presented primary end outcomes, with an early occurrence of 6.3%.

Cumulative primary end point incidence at long term in MED, PCI and CABG was similar at secondary analysis. We should note that periprocedural MI was the only event in 40.5% of INV-CABG cases and in 16.3% of INV-PCI (separately). INV-PCI and INV-CABG were associated with greater early risk and lower late risk vs. CON.

Conclusions

Revascularization with CABG and PCI in INV patients was associated with higher incidence of cardiovascular events, especially periprocedural MI. However, this event incidence saw a reduction at long term vs. the conservative strategy. We should not overlook the non-random nature of these outcomes, especially considering that patients undergoing CABG had more severe CAD, which leads to higher adverse outcomes. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial.

Reference: Redfors, B, Stone, G, Alexander, J. et al. Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial. J Am Coll Cardiol. 2024 Feb, 83 (5) 549–558.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...